中药肾康灵干预小儿原发性肾病综合征对CXCL16及ADAM10的影响
发布时间：2018-07-13 10:40
【摘要】：目的：通过观察原发性肾病综合征(Primary Nephrotic Syndrome,PNS)患儿中药肾康灵干预治疗前后血清趋化因子CXCL16和金属蛋白酶ADAM10的水平变化,从分子生物学水平阐明趋化因子CXCL16和金属蛋白酶ADAM10与PNS的相关性及中药肾康灵干预治疗的作用机理,进一步完善PNS的发病机制和中药肾康灵干预治疗的作用机制,为提高小儿PNS的临床疗效及中药新药研创奠定基础。 方法：选取门诊和病房PNS患儿40例,采用简单随机法将病例分为中西医结合治疗组20例(简称治疗组,A组)和西药治疗对照组20例(简称对照组,B组),另选取体检中心健康儿童6例作为健康对照组(简称正常组,C组)。对照组予以单纯西药治疗,治疗组在对照组的治疗基础上加用中药肾康灵冲剂。应用酶联免疫吸附法(ELISA)检测两组治疗前后的血清趋化因子CXCL16和金属蛋白酶ADAM10水平,同时检测血清白蛋白、血脂(胆固醇、甘油三酯)和尿蛋白定量,观察治疗前后检测指标的变化,应用SPSS13.0统计软件对数据进行统计学处理。 结果：①A、B两组治疗前血清CXCL16、ADAM10水平比正常组明显升高。治疗后A、B两组的血清CXCL16、ADAM10比治疗前明显下降(P均0.01),且A组的血清CXCL16水平明显低于B组(P0.05)。②A、B两组治疗后的血胆固醇、甘油三酯和尿蛋白定量均明显低于治疗前(P0.01和P0.05),血清白蛋白显著上升(P0.01和P0.05)。治疗后A、B两组相比,A组在降低血胆固醇、甘油三酯和升高血清白蛋白方面优于B组(P0.01和P0.05)。 结论：PNS患儿存在着血清CXCL16、ADAM10异常升高的表现,说明血清CXCL16、 ADAM10参与了PNS的发病机制：CXCL16、ADAM10作为吞噬肾脏损伤关键因子ox-LDL的重要成分,能促进肾脏炎症因子的粘附、聚集。中药肾康灵冲剂治疗小儿PNS能显著降低血清CXCL16、ADAM10的水平,降低异常升高的尿蛋白、血脂,升高血白蛋白,从而改善患儿病情,这可能与清除吞噬ox-LDL的血清CXCL16而发挥整体作用有关。
[Abstract]:Objective: to observe the changes of serum chemokine CXCL16 and metalloproteinase ADAM10 in children with primary nephrotic syndrome (PNS) before and after intervention with Shenkangling. To elucidate the correlation between CXCL16 and ADAM10 and PNS and the mechanism of Shenkangling intervention therapy from the molecular biological level, and to improve the pathogenesis of PNS and the mechanism of Shenkangling intervention therapy. To improve the clinical efficacy of children with PNS and to establish a foundation for the development of new Chinese medicine. Methods: 40 children with PNS in outpatients and wards were selected. The patients were randomly divided into two groups: the treatment group (group A) and the control group (group B). 6 healthy children in the physical examination center were selected as the healthy control group. (referred to as normal group C). The control group was treated with simple western medicine, and the treatment group was treated with Shenkangling granule on the basis of the treatment in the control group. The levels of serum chemokine CXCL16 and metalloproteinase ADAM10 were measured by enzyme-linked immunosorbent assay (Elisa) before and after treatment. Serum albumin, serum lipid (cholesterol, triglyceride) and urine protein were measured. The changes of the indexes before and after treatment were observed. SPSS 13.0 statistical software was used to process the data. Results the serum CXCL16 ADAM10 level in the two groups was significantly higher than that in the normal group before treatment. After treatment, the serum CXCL16ADAM10 of AXCL16ADAM10 in group A was significantly lower than that before treatment (P0.01), and the level of serum CXCL16 in group A was significantly lower than that in group B (P0.05). Triglyceride and urine protein were significantly lower than before treatment (P0.01 and P0.05), serum albumin significantly increased (P0.01 and P0.05). After treatment, group A was superior to group B in lowering serum cholesterol, triglyceride and raising serum albumin (P0.01 and P0.05). Conclusion there is abnormal increase of serum CXCL16ADAM10 in children with PNS, which suggests that serum CXCL16 and ADAM10 are involved in the pathogenesis of PNS: CXCL16ADAM10 is an important component of ox-LDL, which can promote the adhesion and aggregation of renal inflammatory factors. Shenkangling granule could significantly reduce the level of serum CXCL16ADAM10, decrease the abnormal increase of urinary protein, blood lipid and serum albumin, thus improve the condition of children, which may be related to the clearance of ox-LDL serum CXCL16 and play a whole role.
【学位授予单位】：福建中医药大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R272
本文编号：2119077
[Abstract]:Objective: to observe the changes of serum chemokine CXCL16 and metalloproteinase ADAM10 in children with primary nephrotic syndrome (PNS) before and after intervention with Shenkangling. To elucidate the correlation between CXCL16 and ADAM10 and PNS and the mechanism of Shenkangling intervention therapy from the molecular biological level, and to improve the pathogenesis of PNS and the mechanism of Shenkangling intervention therapy. To improve the clinical efficacy of children with PNS and to establish a foundation for the development of new Chinese medicine. Methods: 40 children with PNS in outpatients and wards were selected. The patients were randomly divided into two groups: the treatment group (group A) and the control group (group B). 6 healthy children in the physical examination center were selected as the healthy control group. (referred to as normal group C). The control group was treated with simple western medicine, and the treatment group was treated with Shenkangling granule on the basis of the treatment in the control group. The levels of serum chemokine CXCL16 and metalloproteinase ADAM10 were measured by enzyme-linked immunosorbent assay (Elisa) before and after treatment. Serum albumin, serum lipid (cholesterol, triglyceride) and urine protein were measured. The changes of the indexes before and after treatment were observed. SPSS 13.0 statistical software was used to process the data. Results the serum CXCL16 ADAM10 level in the two groups was significantly higher than that in the normal group before treatment. After treatment, the serum CXCL16ADAM10 of AXCL16ADAM10 in group A was significantly lower than that before treatment (P0.01), and the level of serum CXCL16 in group A was significantly lower than that in group B (P0.05). Triglyceride and urine protein were significantly lower than before treatment (P0.01 and P0.05), serum albumin significantly increased (P0.01 and P0.05). After treatment, group A was superior to group B in lowering serum cholesterol, triglyceride and raising serum albumin (P0.01 and P0.05). Conclusion there is abnormal increase of serum CXCL16ADAM10 in children with PNS, which suggests that serum CXCL16 and ADAM10 are involved in the pathogenesis of PNS: CXCL16ADAM10 is an important component of ox-LDL, which can promote the adhesion and aggregation of renal inflammatory factors. Shenkangling granule could significantly reduce the level of serum CXCL16ADAM10, decrease the abnormal increase of urinary protein, blood lipid and serum albumin, thus improve the condition of children, which may be related to the clearance of ox-LDL serum CXCL16 and play a whole role.
【学位授予单位】：福建中医药大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R272
【参考文献】
相关期刊论文 前8条
1 郑健;;小儿原发性肾病综合征中医辨证施治的临床思维[J];中华中医药杂志;2007年04期
2 郑健,廖国华,王智,吴群励;小儿频复发性肾病中医证型与病理类型的相关性分析[J];福建中医学院学报;2005年01期
3 郑健;褚克丹;林青;艾斯;吴群励;;肾康灵治疗小儿频复发性肾病30例临床研究[J];福建中医学院学报;2009年02期
4 陈娣;肖婧;张林娟;吕永曼;邵菊芳;;α3β1整合素在糖尿病大鼠肾脏的表达及其与足细胞减少的关系[J];医学分子生物学杂志;2007年04期
5 魏瑰娜;难治性肾病综合征的发病机制新进展[J];国外医学.泌尿系统分册;2004年01期
6 洪亦眉;陈朝红;;足细胞损伤的病因和发病机制[J];肾脏病与透析肾移植杂志;2009年01期
7 刘雅清;纪泽泉;;足细胞与足细胞病[J];肾脏病与透析肾移植杂志;2011年01期
8 鲁艳芳;袁军;;足细胞相关分子与蛋白尿的关系[J];中国中西医结合儿科学;2009年01期
相关硕士学位论文 前2条
1 艾斯;益肾活血中药肾康灵干预小儿频复发性肾病与NF-κB、TXB_2、6-keto-PGF_（1α）的临床研究[D];福建中医学院;2008年
2 庄晓郑;中药肾康灵冲剂干预儿童频复发性肾病与脂蛋白α的临床研究[D];福建中医学院;2009年
，本文编号：2119077
本文链接：https://www.wllwen.com/yixuelunwen/eklw/2119077.html
最近更新
教材专著
